ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
17.932,17
-1,10%
S&P 500
5.035,69
-1,57%
Dow Jones
37.815,92
-1,49%
Euro vs US Dollar
1,06667
0,00%
Bitcoin
60.529,75
-0,12%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. REGENXBIO Inc (RGNX)

  7. REGENXBIO Inc (RGNX) News

RGNX REGENXBIO Inc

15,35
-0,70 (-4,36%)
30 Apr 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
REGENXBIO Inc RGNX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
-0,70 -4,36% 15,35 23:30:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
15,79 15,33 16,01 15,35 16,05
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
24.4.202413:05PRNUSREGENXBIO to Participate in Chardan's 8th Annual Genetic..
28.3.202412:05PRNUSREGENXBIO Announces Lancet Publication of Phase I/IIa Study..
27.3.202421:05PRNUSREGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD..
11.3.202413:00EDGAR2Form 8-K - Current report
11.3.202412:05PRNUSREGENXBIO to Participate in Upcoming Investor Conferences
08.3.202412:09EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08.3.202400:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.3.202412:03EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
07.3.202405:20PRNUSREGENXBIO Announces Pricing of Upsized Public Offering of..
06.3.202422:23EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06.3.202422:10PRNUSREGENXBIO Announces Proposed Public Offering of Common Stock
05.3.202422:26EDGAR2Form 144 - Report of proposed sale of securities
05.3.202413:05PRNUSREGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM..
29.2.202422:57PRNUSREGENXBIO to Host Webcast Event to Discuss New Interim..
27.2.202422:54EDGAR2Form S-8 - Securities to be offered to employees in employee..
27.2.202422:10EDGAR2Form 8-K - Current report
27.2.202422:05PRNUSREGENXBIO Reports Fourth Quarter and Full Year 2023..
21.2.202413:05PRNUSREGENXBIO to Host Conference Call on February 27 to Discuss..
17.2.202400:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.2.202417:40PRNUSREGENXBIO Announces Pivotal Trial of RGX-121 for the..
07.2.202413:05PRNUSREGENXBIO Announces Completion of Enrollment in Cohort 2 and..
31.1.202413:05PRNUSREGENXBIO Announces Presentations at the 20th Annual..
19.1.202400:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.1.202422:22EDGAR2Form 144 - Report of proposed sale of securities
16.1.202420:47PRNUSREGENXBIO Announces Positive Interim Data from Phase II..
10.1.202413:05PRNUSREGENXBIO Announces Presentation at the Hawaiian Eye and..
08.1.202413:05PRNUSU.S. District Court Issues Decision on REGENXBIO and..
04.1.202422:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202422:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202422:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.1.202422:21EDGAR2Form 144 - Report of proposed sale of securities
21.12.202319:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19.12.202322:29EDGAR2Form 144 - Report of proposed sale of securities
29.11.202313:05PRNUSREGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE®..
08.11.202322:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.11.202322:10EDGAR2Form 8-K - Current report
08.11.202322:05PRNUSREGENXBIO Announces Updated Strategic Plans and Third..
07.11.202313:05PRNUSREGENXBIO to Participate in Upcoming Investor Conferences
03.11.202323:53PRNUSREGENXBIO Presents Positive One Year Data from Phase II..
01.11.202312:05PRNUSREGENXBIO to Host Conference Call on November 8 to Discuss..
30.10.202312:05PRNUSREGENXBIO Announces Presentations at the American Academy of..
05.10.202313:05PRNUSREGENXBIO to Participate in the Jefferies CNS/Neuro Summit
03.10.202322:05PRNUSREGENXBIO Presents Interim Clinical Data from Phase I/II..
26.9.202313:05PRNUSREGENXBIO Announces Presentations at the 28th Annual..
05.9.202313:05PRNUSREGENXBIO to Participate in Upcoming Investor Conferences
01.9.202322:42EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
01.9.202322:12EDGAR2Form 8-K - Current report
30.8.202313:05PRNUSInitial Clinical Data of First Pediatric CLN2 Patient Dosed..
23.8.202322:05PRNUSREGENXBIO Announces Presentations at the Society for the..

Kürzlich von Ihnen besucht

NASDAQ
RGNX
REGENXBIO
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten